Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Guggenheim Capital LLC

Guggenheim Capital LLC decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 31.6% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 5,235 shares of the company's stock after selling 2,414 shares during the period. Guggenheim Capital LLC's holdings in Medpace were worth $1,739,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Lindbrook Capital LLC boosted its holdings in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after acquiring an additional 29 shares during the last quarter. HBK Sorce Advisory LLC lifted its position in Medpace by 0.5% during the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock valued at $1,789,000 after purchasing an additional 29 shares during the period. Assetmark Inc. boosted its holdings in Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after purchasing an additional 29 shares during the last quarter. Proficio Capital Partners LLC boosted its holdings in Medpace by 4.1% in the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock valued at $243,000 after purchasing an additional 29 shares during the last quarter. Finally, Schulhoff & Co. Inc. grew its position in Medpace by 1.2% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock worth $874,000 after purchasing an additional 30 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Trading Down 2.1 %

MEDP stock traded down $6.40 during midday trading on Friday, reaching $296.49. The stock had a trading volume of 168,535 shares, compared to its average volume of 338,150. The company has a market cap of $8.96 billion, a price-to-earnings ratio of 23.48, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $459.77. The company's fifty day simple moving average is $314.64 and its 200 day simple moving average is $332.04.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The business had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. During the same period in the previous year, the firm posted $3.20 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. William Blair reaffirmed a "market perform" rating on shares of Medpace in a report on Tuesday. TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and cut their price objective for the company from $370.00 to $328.00 in a report on Monday, April 14th. Leerink Partnrs raised shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Robert W. Baird cut their price target on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research note on Wednesday. Finally, Truist Financial lowered their price target on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research report on Wednesday. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $349.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.